Evidence map›Paper›PMID 38251369›Full record

ArticlePathogens (Basel, Switzerland)2024

Heat Inactivation of Nipah Virus for Downstream Single-Cell RNA Sequencing Does Not Interfere with Sample Quality.

Adam J Hume, Judith Olejnik, Mitchell R White, Jessie Huang, Jacquelyn Turcinovic, Baylee Heiden, Pushpinder S Bawa, Christopher J Williams, Nickolas G Gorham, Yuriy O Alekseyev and 3 more

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Adam J HumeDepartment of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.ORCID 0000-0001-8454-3472
Judith OlejnikDepartment of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.ORCID 0000-0002-1748-7981
Mitchell R WhiteDepartment of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Jessie HuangCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Jacquelyn TurcinovicDepartment of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Baylee HeidenDepartment of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.ORCID 0000-0001-7087-6997
Pushpinder S BawaCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Christopher J WilliamsDepartment of Medicine, Single Cell Sequencing Core Facility, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Nickolas G GorhamMicroarray and Sequencing Resource Core Facility, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
Yuriy O AlekseyevDepartment of Pathology and Laboratory Medicine, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.
John H ConnorDepartment of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.ORCID 0000-0002-8867-7256
Darrell N KottonCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Elke MühlbergerDepartment of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA 02118, USA.ORCID 0000-0003-3547-9376

Funding

Regulatory Compliance CoreUC7AI095321 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Adam Carter · 2014 to 2026
$159.3M
Whole Animal Imaging CoreUC7AI070088 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MUHLBERGER, ELKE C · 2006 to 2013
$57.9M
Derivation of Transplantable Lung Epithelial Progenitors from iPS CellsR01HL095993 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Darrell N. Kotton · 2009 to 2026
$7.5M
Advancement of poxvirus inhibitorR01AI151559 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BROWN, LAUREN ELAINE, CONNOR, JOHN H · 2020 to 2025
$5.8M
NATIONAL BIOREPOSITORY OF LUNG DISEASE-SPECIFIC HUMAN INDUCED PLURIPOTENT STEM CELLS:THE PURPOSE OF THIS RESOURCE IS TO BUILD AND SUPPORT A CRITICAL75N92020C00005 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI N/A, N/A · 2021 to 2024
$2.6M
Elucidating the immune response of Schreiber's bats to Lloviu virus infection in vitro and in vivoR21AI169646 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MUHLBERGER, ELKE C · 2022 to 2023
$430k
Gates Foundation INV-048926NHLBI NIH HHS 75N92020C00005NHLBI NIH HHS R01 HL095993NIAID NIH HHS R01 AI151559NIAID NIH HHS R21 AI169646NIAID NIH HHS UC7 AI070088NIH HHS NO1 75N92020C00005NIH HHS R01HL095993NIH HHS UC7AI070088
6 · The paper itself

Abstract

Single-cell RNA sequencing (scRNA-seq) technologies are instrumental to improving our understanding of virus-host interactions in cell culture infection studies and complex biological systems because they allow separating the transcriptional signatures of infected versus non-infected bystander cells. A drawback of using biosafety level (BSL) 4 pathogens is that protocols are typically developed without consideration of virus inactivation during the procedure. To ensure complete inactivation of virus-containing samples for downstream analyses, an adaptation of the workflow is needed. Focusing on a commercially available microfluidic partitioning scRNA-seq platform to prepare samples for scRNA-seq, we tested various chemical and physical components of the platform for their ability to inactivate Nipah virus (NiV), a BSL-4 pathogen that belongs to the group of nonsegmented negative-sense RNA viruses. The only step of the standard protocol that led to NiV inactivation was a 5 min incubation at 85 °C. To comply with the more stringent biosafety requirements for BSL-4-derived samples, we included an additional heat step after cDNA synthesis. This step alone was sufficient to inactivate NiV-containing samples, adding to the necessary inactivation redundancy. Importantly, the additional heat step did not affect sample quality or downstream scRNA-seq results.

Indexed as

Hot TemperatureNipah VirusSequence Analysis, RNASingle-Cell AnalysisVirus InactivationAnimalsHenipavirus InfectionsHumans10x GenomicsBSL-4 pathogensheat inactivationiPSC-derived alveolar type 2 cellsNipah virusnonsegmented negative sense RNA virusesscRNA-seqsingle-cell RNA sequencingVSV

Identifiers

PMID38251369
PMCPMC10818917

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.